John T Sisko

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 71(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

Years Active: 1990-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9643982 - Fused tricyclic heterocyclic compounds as HIV integrase inhibitors (2017-05-09),

2. 8404856 - Non-nucleoside reverse transcriptase inhibitors (2013-03-26),

3. 7807684 - HIV reverse transcriptase inhibitors (2010-10-05),

4. 7265134 - Tyrosine kinase inhibitors (2007-09-04),

5. 7115597 - Tyrosine kinase inhibitors (2006-10-03),

6. 6376496 - Inhibitors of prenyl-protein transferase (2002-04-23),

7. 6358956 - Inhibitors of prenyl-protein transferase (2002-03-19),

8. 6355643 - Inhibitors of prenyl-protein transferase (2002-03-12),

9. 6335343 - Inhibitors of prenyl-protein transferase (2002-01-01),

10. 6127390 - Inhibitors of prenyl-protein transferase (2000-10-03),

11. 4963534 - Process for solubilizing polyanoinic bacterial polysaccharides in (1990-10-16),

Title: The Innovative Contributions of John T. Sisko

Introduction

John T. Sisko is a notable inventor based in Lansdale, PA (US), recognized for his significant contributions to the field of pharmaceutical chemistry. With a total of 11 patents to his name, Sisko has focused his research on developing compounds that target HIV, showcasing his commitment to addressing critical health challenges.

Latest Patents

Among his latest patents, Sisko has developed Fused Tricyclic Heterocyclic Compounds as HIV Integrase Inhibitors. This invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I) and their pharmaceutically acceptable salts. The invention also includes compositions that utilize these derivatives for treating or preventing HIV infection in subjects. Another significant patent involves Non-Nucleoside Reverse Transcriptase Inhibitors, which are heteroaromatic compounds of Formula (I) that inhibit HIV reverse transcriptase. These compounds are useful in the treatment and prevention of HIV infection and AIDS, highlighting Sisko's impactful work in the pharmaceutical industry.

Career Highlights

Throughout his career, John T. Sisko has worked with prominent companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of antiviral medications.

Collaborations

Sisko has collaborated with esteemed colleagues, including Thomas Joseph Tucker and Anthony M. Smith. These partnerships have further enhanced his research efforts and innovation in the pharmaceutical sector.

Conclusion

John T. Sisko's work exemplifies the spirit of innovation in the fight against HIV and AIDS. His patents and collaborations reflect a dedication to improving health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.